IonGate wins the Contest “365 Landmarks in the Land of Ideas”

Frankfurt/Main (Germany), 26th November 2007. IonGate Biosciences GmbH was elected by the initiative “Germany - Land of Ideas” as landmark in 2008. The motto “Surfing into the world of drugs” received the jury’s acclaim. IonGate will open it's doors to the public on November 17th 2008 and celebrate the award with an open day, offering visitors the rare opportunity to explore a highly innovative biotech company. A comprehensible program will focus on IonGate's SURFE2R Technology. SURFE2R enables scientists to develop new drugs, for example for the treatment of Alzheimer or coronary disease, quicker and more reliable.

In 2008, a leap year, the nationwide event series “365 Landmarks in the Land of Ideas” will present 365 plus 1 landmarks where the future is shaped.
The great number of over 1,500 entries even as the contest entered its third year clearly shows the importance of Germany’s largest event series. It continues the project partnership between the “Germany - Land of Ideas” nation-branding initiative and Deutsche Bank to further promote creative landmarks and their ideas.

In the scope of “Germany - Land of Ideas” initiatives, institutions, clubs and associations developing innovations and creating ideas are awarded. These include public and private institutions, universities and research institutes, and companies, as well as social and cultural projects.

Contact
Wolfgang Lerch
Managing Director
IonGate Biosciences GmbH
Industriepark Hoechst / Building D528
65926 Frankfurt/Main
Germany

phone +49.69.305.85 400
fax +49.69.305.85 444
email info@iongate.net

Media inquiries
Dr. Holger Bengs
Biotech Consulting

phone +49.69.619.94 273
fax +49.69.619.94 249
email info@holgerbengs.de

About IonGate Biosciences GmbH

IonGate Biosciences GmbH develops, produces and markets innovative screening technologies to investigate transporters and is the worldwide leading company in this area.

Transporters are essential for the metabolic functions of the cell, information proc¬essing in the entire organism and play a fundamental role to the health of humans. Due to their difficult experimental accessibility, transporters are underrepresented in current drug screening processes so far. For the first time IonGate provides with SURFE2R One and SURFE2R Workstation a highly precise functional screening of transporters in higher throughput and thereby positions itself as a strong partner for the pharmaceutical industry. With its SURFE2R Workstation IonGate has created a technological basis for an automated and robust analytical technique. The company supplies complete solutions. In addition to instruments, disposables and reagents, IonGate provides its customers with complete solutions ranging from individual consulting services to the design and implementation of customized applications.

IonGate Biosciences GmbH is a venture capital-financed biotechnology company located in Frankfurt/Main in Germany. In addition to the main financier and leading partner Heidelberg Innovation, the KfW holds a stake in IonGate. The company was established in 2000 and currently employs more than 30 staff members.

This release was published on openPR.